Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NeurAxis, Inc.

< Previous 1 2 Next >
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Announces $5.0 Million Registered Direct Offering
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
From NeurAxis, Inc.
Via GlobeNewswire
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Inc. Issues Letter to Shareholders
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
From NeurAxis, Inc.
Via GlobeNewswire
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
From NeurAxis, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.